Ningbo Menovo Pharmaceutical Co (SHSE:603538) Long-Term Debt: ¥40 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603538 Ningbo Menovo Pharmaceutical Co Ltd SHSE:603538
74 GF Score
Price ¥28.51
GF Value ¥17.31
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Ningbo Menovo Pharmaceutical Co Long-Term Debt?

Ningbo Menovo Pharmaceutical Co SHSE:603538 -10.01% 74 Long-Term Debt is ¥40 Mil as of Jun. 2026. GuruFocus rates SHSE:603538 with a GF Score™ of 74/100 and a GF Value™ of ¥17.31 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Ningbo Menovo Pharmaceutical Co's Long-Term Debt for the quarter that ended in Jun. 2026 was ¥40 Mil.

Ningbo Menovo Pharmaceutical Co's quarterly Long-Term Debt declined from Dec. 2025 (¥679 Mil) to Mar. 2026 (¥544 Mil) and declined from Mar. 2026 (¥544 Mil) to Jun. 2026 (¥40 Mil).

Ningbo Menovo Pharmaceutical Co's annual Long-Term Debt declined from Dec. 2023 (¥744 Mil) to Dec. 2024 (¥652 Mil) but then increased from Dec. 2024 (¥652 Mil) to Dec. 2025 (¥679 Mil).

Ningbo Menovo Pharmaceutical Co  (SHSE:603538) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Ningbo Menovo Pharmaceutical Co Long-Term Debt Related Terms

Ningbo Menovo Pharmaceutical Co Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Ningbo Menovo Pharmaceutical Co's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ningbo Menovo Pharmaceutical Co Long-Term Debt Chart

Ningbo Menovo Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 727.31 675.25 743.96 651.62 678.59

Ningbo Menovo Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 626.50 584.74 678.59 544.11 39.50
SHSE:603538
74GF Score
Ningbo Menovo Pharmaceutical Co Ltd SHSE:603538
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of ¥40 Mil mean?
Ningbo Menovo Pharmaceutical Co (SHSE:603538) has a Long-Term Debt of ¥40 Mil as of Jun. 2026.
Is Ningbo Menovo Pharmaceutical Co's Long-Term Debt too high?
Ningbo Menovo Pharmaceutical Co's current Long-Term Debt is ¥40 Mil. Overall, Ningbo Menovo Pharmaceutical Co has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ningbo Menovo Pharmaceutical Co's Long-Term Debt compare to ZTS?
Ningbo Menovo Pharmaceutical Co's Long-Term Debt of ¥40 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Ningbo Menovo Pharmaceutical Co's current Long-Term Debt is ¥40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ningbo Menovo Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Ningbo Menovo Pharmaceutical Co (SHSE:603538) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥17.31, compared to a current price of ¥28.51 — trading 64.7% above its estimated fair value. The current Long-Term Debt is ¥40 Mil. Ningbo Menovo Pharmaceutical Co's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Ningbo Menovo Pharmaceutical Co (SHSE:603538), the current Long-Term Debt is ¥40 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ningbo Menovo Pharmaceutical Co (SHSE:603538) Overvalued in 2026?

Based on GuruFocus' analysis, Ningbo Menovo Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥28.51 is trading 64.7% above its estimated GF Value™ of ¥17.31. GuruFocus considers Ningbo Menovo Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for SHSE:603538:

  • Long-Term Debt: ¥40 Mil
  • GF Value™: ¥17.31 vs. price of ¥28.51 (64.7% above fair value)
  • GF Score™: 74/100 with 4 warning signs

No single metric tells the full story. See the SHSE:603538 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ningbo Menovo Pharmaceutical Co Business Description

Address No.999,Yangfan Road, Room 1406, No.1, High-tech Zone, Ningbo, CHN, 315040
Ningbo Menovo Pharmaceutical Co Ltd is a China-based company is engaged in the research and development, pilot, production and sales of pharmaceutical intermediates, APIs and finished drugs. Its products line includes cardiovascular, central nervous, respiratory, anti-tumor, anti-infective, digestive system, geriatric diseases and anti-viral systems.
74GF Score

Get the complete analysis for SHSE:603538

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥28.51
Price
¥17.31
GF Value